ValorQ4, 24Q1, 25Q2, 25Q3, 25Q4, 25Q1, 26TTMDespesas comerciais, gerais e administrativas2.42 B2.47 B2.75 B2.74 B3.13 B2.93 B11.56 BPesquisa e desenvolvimento3.21 B4.31 B3.49 B4.12 B4.33 B4.09 B16.04 BLucro operacional4.6 B3.7 B6.87 B7.37 B7.89 B8.91 B31.03 BLucro não operacional, total-110.1 M-239 M-90.6 M-133.1 M-108.3 M-65 M-397 MDespesa com juros, líquida de juros capitalizados224.7 M243.7 M249 M179.6 M222.7 M——Receitas não operacionais, líquidas das despesas com juros-84.6 M-235.5 M10.4 M46.3 M-108.3 M-65 M-116.6 MReceitas/despesas incomuns-25.5 M-3.5 M-101 M-179.4 M———Lucro antes dos impostos5.04 B3.46 B6.78 B7.23 B8.27 B8.85 B31.13 BParticipação no lucro———————Impostos628.9 M696.8 M1.12 B1.65 B1.63 B1.45 B5.85 BParticipação de minoritários———————Outras receitas/despesas após impostos———————Lucro líquido antes das operações descontinuadas4.41 B2.76 B5.66 B5.58 B6.64 B7.4 B25.28 BOperações descontinuadas———————Lucro líquido4.41 B2.76 B5.66 B5.58 B6.64 B7.4 B25.28 BAjuste de diluição———————Dividendos de ações preferenciais———————Lucro líquido diluído disponível aos acionistas4.41 B2.76 B5.66 B5.58 B6.64 B7.4 B25.28 BLucro básico por ação4.93.076.36.227.418.2728.2Lucro diluído por ação4.883.066.296.217.398.2628.15Número médio de ações básicas900.61 M898.7 M897.9 M896.9 M897.3 M894.5 M—Ações diluídas904.06 M900.6 M899.8 M898.8 M899.3 M895.9 M—EBITDA5.08 B4.16 B7.35 B7.84 B8.47 B9.42 B33.08 BEBIT4.6 B3.7 B6.87 B7.37 B7.89 B8.91 B31.03 BCusto da receita2.4 B2.22 B2.45 B3.01 B3.37 B3.58 B12.4 BOutros componentes do custo———————Amortização e depreciação (fluxo de caixa)484.8 M462.8 M478.3 M470 M585.7 M509 M2.04 B
Eli Lilly and Company Common Stock
Eli Lilly and Company, doing business as Lilly, is an American multinational pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries. The company was founded in 1876 by Eli Lilly, a pharmaceutical chemist and Union army veteran during the American Civil War for whom the company was later named.
The company is ranked 4th on the list of largest biomedical companies by revenue and is the most valuable pharmaceutical company worldwide. It is ranked 100th on the Fortune 500 and 138th on the Forbes Global 2000. In November 2025, the company reached a $1 trillion market capitalization, the first health-care company in the world to do so.
The company's primary products are tirzepatide for the treatment of type 2 diabetes, weight loss, and obstructive sleep apnea; abemaciclib for the treatment of advanced or metastatic breast cancers; dulaglutide for the treatment of type 2 diabetes; ixekizumab for the treatment of autoimmune diseases; and empagliflozin for the treatment of type 2 diabetes.